3/25
11:17 am
nrsn
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
3/24
09:00 am
nrsn
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
Neutral
Report
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
3/18
08:12 am
nrsn
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference [Yahoo! Finance]
Medium
Report
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference [Yahoo! Finance]
3/18
08:00 am
nrsn
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Medium
Report
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
3/17
09:03 am
nrsn
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
3/16
12:04 pm
nrsn
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity [Yahoo! Finance]
Medium
Report
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity [Yahoo! Finance]
3/16
11:33 am
nrsn
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
Medium
Report
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
3/10
08:03 am
nrsn
NeuroSense Therapeutics (NRSN) is now covered by Roth Mkm. They set a "buy" rating and a $3.00 price target on the stock.
Medium
Report
NeuroSense Therapeutics (NRSN) is now covered by Roth Mkm. They set a "buy" rating and a $3.00 price target on the stock.
3/9
02:46 pm
nrsn
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
3/9
11:30 am
nrsn
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference [Yahoo! Finance]
Low
Report
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference [Yahoo! Finance]
3/9
11:07 am
nrsn
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
Low
Report
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
2/18
09:05 am
nrsn
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
High
Report
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
2/9
09:20 am
nrsn
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
High
Report
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
1/21
08:30 am
nrsn
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Medium
Report
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
1/8
09:23 am
nrsn
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB [Yahoo! Finance]
Medium
Report
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB [Yahoo! Finance]
1/8
08:45 am
nrsn
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Medium
Report
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
1/3
01:08 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at
Wall S
High
Report
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at
Wall S